ASTRAZENECA PLC

AZN
Real-time Estimate Quote. Real-time Estimate  - 03/02 11:30:00 am
6882.5GBX -1.40%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (97.3%). Net sales break down by treatment area between oncology (41.9%), cardiovascular, renal and metabolic diseases (27.4%), respiratory and autoimmune diseases (20.7%), and other (10%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (2.7%).
Net sales are distributed geographically as follows: the United Kingdom (6.5%), Continental Europe (18.2%), Americas (38.7%) and Africa/Asia/Australia (36.6%).

Number of employees : 76 100 people.
Sales per Business
20192020
GBP
(in Million)
%GBP
(in Million)
%
Oncology 6,79435.5% 8,46140.8%
Cardiovascular, Renal & Metabolism 5,41328.3% 5,53426.7%
Respiratory 4,22622.1% 4,17720.1%
Other Diseases 2,03910.7% 2,0179.7%
Externalisation Revenue 641.983.4% 566.932.7%
Sales per region
2020
GBP
(in Million)
%
United States 6,98333.6%
China 4,16820.1%
Japan 2,0029.6%
United Kingdom 1,3586.5%
Other Asia, Africa and Australasia 1,1965.8%
Other Continental Europe 1,0855.2%
Sweden 800.093.9%
Germany 730.693.5%
Other Americas 593.442.9%
France 509.222.5%
Managers
Name Title
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
José Baselga Executive VP-Oncology Research & Development
Henry D. Cremisi Medical Director
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability
Marcus Wallenberg Independent Non-Executive Director
Graham Andrew Chipchase Senior Independent Non-Executive Director
Shareholders
Name Equities %
Wellington Management Co. LLP 68,525,329 5.22%
Capital Research & Management Co. (World Investors) 56,102,804 4.27%
BlackRock Investment Management (UK) Ltd. 54,582,684 4.16%
Investor AB (Investment Company) 51,587,810 3.93%
The Vanguard Group, Inc. 36,392,318 2.77%
Norges Bank Investment Management 31,575,000 2.41%
BlackRock Fund Advisors 24,597,820 1.87%
BlackRock Advisors (UK) Ltd. 16,674,294 1.27%
Fidelity Management & Research Co. LLC 15,320,464 1.17%
SSgA Funds Management, Inc. 13,805,160 1.05%
Company contact information
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire


Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : http://www.astrazeneca.com
Markets and indexes
-
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- ISIN Code :  GB0009895292
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  AZN
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTRAZENECA PLC-3.80%127 813
JOHNSON & JOHNSON1.23%418 801
ROCHE HOLDING AG-2.83%281 718
NOVARTIS AG-4.73%196 893
ABBVIE INC.1.18%191 439
PFIZER INC.-9.02%187 968
ELI LILLY AND COMPANY22.29%187 563
MERCK & CO., INC.-11.52%183 144
NOVO NORDISK A/S5.13%167 918
BRISTOL-MYERS SQUIBB COMPANY-1.13%138 080
AMGEN INC.-2.17%131 131
ASTRAZENECA PLC-4.70%127 813
SANOFI-2.90%115 776
GLAXOSMITHKLINE PLC-10.54%83 586
JIANGSU HENGRUI MEDICINE CO., LTD.-10.00%82 363
CHUGAI PHARMACEUTICAL CO., LTD.-13.34%73 523
BAYER AG8.69%62 004
DAIICHI SANKYO COMPANY, LIMITED-12.45%55 726
TAKEDA PHARMACEUTICAL COMPANY LIMITED-3.78%52 973
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED4.26%29 912
ASTELLAS PHARMA INC.7.31%29 797
Brand Portfolio
ACERTA PHARMA
ACERTA PHARMA
ALMIRALL
ALMIRALL
ARDEA BIOSCIENCES
ARDEA BIOSCIENCES
ASTRAZENECA
ASTRAZENECA
ZS PHARMA
ZS PHARMA
» More brands of AstraZeneca PLC